Alison Balfour

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

Naomi Schlesinger, Eduardo Mysler, Hsiao‐Yi Lin et al. · Annals of the Rheumatic Diseases · 2011 · 236 citations · Full text

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

Andrew Blauvelt, J.‐P. Lacour, Joseph F. Fowler et al. · British Journal of Dermatology · 2018 · 145 citations

Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: A 12‐week, randomized, open‐label, dose‐titration study <i>versus</i> sevelamer hydrochloride

J. F. Chen, Shou-Shan Chiang, HUNG‐CHUN CHEN et al. · Nephrology · 2011 · 26 citations

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

Andrew Blauvelt, Craig L. Leonardi, Norman Gaylis et al. · BioDrugs · 2021 · 19 citations · Full text

Canakinumab Reduces The Risk Of Acute Gouty Arthritis Flares During Initiation Of Allopurinol Therapy: Results Of A Double-blind, Randomised Study

Naomi Schlesinger, Eduardo Mysler, Heng‐Kuei Lin et al. · Journal of Allergy and Clinical Immunology · 2011 · 10 citations · Full text